NEWS DESK
Building your stock news briefing…
Gilead Sciences, Inc. - Common Stock (GILD) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently positive earnings tone.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥.
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai
This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.
Gilead Sciences, Inc. (NASDAQ) on Tuesday released results from the Phase 3 IDEAL study in people with primary biliary cholangitis (PBC).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥.
Gilead Sciences recently announced strong Phase 3 data for its drug Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC), demonstrating significant improvement in alkaline phosphatase normalization, a key indicator of disease progression. This positive clinical outcome strengthens confidence in Livdelzi's potential as a treatment option for PBC patients. While the stock shows a mixed or range-bound trend, these clinical results could act as a catalyst for renewed investor interest. Traders may watch for how the market incorporates these Phase 3 results alongside upcoming regulatory decisions and launch plans, particularly given the current absence of decisive price movement or momentum indicators.
GILD is not giving a fully clean trend read right now, which makes the quality of follow-through especially important.
Momentum is not especially stretched right now, so price behaviour around fresh headlines may matter more than an extreme oscillator reading.
Last price is $127.58, versus MA50 at — and MA200 at —. Relative to those reference points, GILD is — vs MA50 and — vs MA200.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥.
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai